Add-on effects of Chinese herbal medicine external application (FZHFZY) to topical urea for mild-to-moderate psoriasis vulgaris: Protocol for a double-blinded randomized controlled pilot trial embedded with a qualitative study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0297834 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Junyue Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: The China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, Victori…. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Psoriasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2022 TCM Innovation Team and Talent Support Program of the State Administration of Traditional Chinese Medicine, Guangzhou Science and Technology Planning Project, Department of Science and Technology of Guangdong Province.
Abstract (Originalsprache)
Psoriasis vulgaris is a chronic dermatological disease with a high global prevalence. It significantly reduces patients’ quality of life and is associated with a substantial economic burden. Conventional therapies for mild-to-moderate psoriasis are often associated with insufficient long-term symptomatic relief and side effects. Chinese herbal medicine (CHM) is commonly used for psoriasis management. A CHM formula, namely Fu zheng he fu zhi yang (FZHFZY), has shown promising treatment effects in clinical practice when used as a bath therapy. However, its efficacy and safety has not been evaluated by a rigorous randomized controlled trial (RCT). Therefore, we designed a double-blinded pilot RCT embedded with a qualitative study on CHM formula FZHFZY plus topical urea for mild-to-moderate psoriasis vulgaris to advance the evidence development and practice of CHM external application for psoriasis. This will be a mixed-method design consisting of a pilot RCT and a qualitative study. The pilot RCT is a two-arm, parallel, placebo-controlled, double-blinded trial. Sixty eligible participants will be randomized at a 1:1 ratio to receive eight weeks’ treatment of either FZHFZY plus 10% urea cream, or placebo plus 10% urea cream, with 12-week follow-up visits after the treatment phase. The CHM or placebo will be administered externally as a bath therapy. Outcome measures include trial feasibility, efficacy and safety. The primary efficacy outcome will be Psoriasis Area Severity Index (PASI). Secondary efficacy outcomes include Physician Global Assessment, PASI-75, PASI-50, Body Surface Area, Dermatology Life Quality Index, Skindex-16, itch visual analogue scale and relapse. The qualitative study will be conducted to collect participants’ feedback on CHM external application and their experience with the pilot RCT. This study will advance the evidence-based clinical practice of using CHM for psoriasis vulgaris and then to support translation of findings into clinical practice in the future. Trial registration number: ChiCTR2200064092 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia.
- The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China.
- Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Guangzhou University of Chinese Medicine, Guangzhou, China.
- State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
ORCID-Profile: Junyue Wang, Charlie Changli Xue
Förderung
- 2022 TCM Innovation Team and Talent Support Program of the State Administration of Traditional Chinese Medicine
- Guangzhou Science and Technology Planning Project
- Department of Science and Technology of Guangdong Province
- Guangdong Provincial Hospital of Chinese Medicine
- China–Australia International Research Centre for Chinese Medicine
Zitieren
APA
Wang, J., Zhang, C. S., Zhang, A. L., Yu, J., Deng, H., Chen, H., Xue, C. C., & Lu, C. (2024). Add-on effects of Chinese herbal medicine external application (FZHFZY) to topical urea for mild-to-moderate psoriasis vulgaris: Protocol for a double-blinded randomized controlled pilot trial embedded with a qualitative study. PLOS ONE. https://doi.org/10.1371/journal.pone.0297834
Vancouver
Wang J, Zhang CS, Zhang AL, Yu J, Deng H, Chen H, et al. Add-on effects of Chinese herbal medicine external application (FZHFZY) to topical urea for mild-to-moderate psoriasis vulgaris: Protocol for a double-blinded randomized controlled pilot trial embedded with a qualitative study. PLOS ONE. 2024. doi:10.1371/journal.pone.0297834
BibTeX
@article{Wang2024,
author = {Wang, Junyue and Zhang, Claire Shuiqing and Zhang, Anthony Lin and Yu, Jingjie and Deng, Hao and Chen, Haiming and Xue, Charlie Changli and Lu, Chuanjian},
title = {Add-on effects of Chinese herbal medicine external application (FZHFZY) to topical urea for mild-to-moderate psoriasis vulgaris: Protocol for a double-blinded randomized controlled pilot trial embedded with a qualitative study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0297834}
}
EUVIMED